MIFH
MYGN icon

Migdal Insurance & Financial Holdings’s Myriad Genetics MYGN Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-36,322
Closed -$1.11M – 642
2021
Q1 		$1.11M Buy
36,322
+22,540
+164% +$640K 0.01% 235
2020
Q4 		$273K Buy
+13,782
New +$223K ﹤0.01% 277

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Migdal Insurance & Financial Holdings's MYGN Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 36,322 shares — an estimated $1.11M sold.

Migdal Insurance & Financial Holdings first reported a position in MYGN in Q4 2020 and held it in 2 quarters. The position peaked at $1.11M in Q1 2021. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 36,322 Myriad Genetics shares in Q2 2021, an estimated $1.11M.
  • Migdal Insurance & Financial Holdings first reported a position in Myriad Genetics in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Myriad Genetics position peaked at $1.11M in Q1 2021.
  • 201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.